About: covid:PMC7280290

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: covid:PMC7280290 Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
Creator	Smith, Ian Barry, Peter Johnston, Stephen Bliss, Judith Christgen, Matthias Dixon, J. Dowsett, Mitch Ellis, Matthew Gluz, Oleg Harbeck, Nadia Jacobs, Samuel Kates, Ronald Kreipe, Hans Kuemmel, Sherko Ma, Cynthia Nitz, Ulrike Robertson, John Suman, Vera Turnbull, Arran
is schema:about of	named entity 'Evidence-based guidelines' named entity 'breast cancer' named entity 'tamoxifen' named entity '1, 2' named entity 'Ki67' named entity 'Group 3' named entity 'Ki67' named entity 'Ki67' named entity 'endocrine' named entity 'Ki67' named entity 'details of the trials' named entity 'tumor' named entity 'postmenopausal women' named entity 'letrozole' named entity 'neoadjuvant chemotherapy' named entity 'PgR' named entity 'case-control' named entity 'neoadjuvant' named entity 'long-term' named entity 'Ki67' named entity 'premenopausal' named entity 'prognosis' named entity 'COVID19' named entity 'tamoxifen' named entity 'breast cancer' named entity 'premenopausal' named entity 'surgical management' named entity 'chemotherapy' named entity 'Ki67' named entity 'Ki67' named entity 'postmenopausal' named entity 'adjuvant' named entity 'Ki67' named entity 'case-control study' named entity 'anastrozole' named entity 'biopsy' named entity 'clinical trials' named entity 'PgR' named entity 'Ki67' named entity 'meta-analysis' named entity 'postmenopausal' named entity 'core biopsy' named entity 'postmenopausal' named entity 'Ki67' named entity 'PgR' named entity 'biopsy' named entity 'PgR' named entity 'postmenopausal' named entity 'PgR' named entity 'Ki67' named entity 'Ki67' named entity 'Group 3' named entity 'Ki67' named entity 'Group 3' named entity '12 weeks' named entity 'tumor size' named entity 'breast cancer' named entity 'anastrozole' named entity 'Ki67' named entity 'postmenopausal' named entity 'Ki67' named entity 'biopsy' named entity 'neoadjuvant' named entity 'Ki67' named entity 'ER+' named entity 'COVID-19 pandemic' named entity 'postmenopausal' named entity 'premenopausal' named entity 'tumor size' named entity 'postmenopausal' named entity 'tumors' named entity 'tumor' named entity 'PgR' named entity 'COVID-19' named entity 'PgR' named entity 'Ki67' named entity 'COVID-19' named entity 'biopsy' named entity 'ER+' named entity 'ER+' named entity 'PgR'

Attributes

Values

Creator

Smith, Ian
Barry, Peter
Johnston, Stephen
Bliss, Judith
Christgen, Matthias
Dixon, J.
Dowsett, Mitch
Ellis, Matthew
Gluz, Oleg
Harbeck, Nadia
Jacobs, Samuel
Kates, Ronald
Kreipe, Hans
Kuemmel, Sherko
Ma, Cynthia
Nitz, Ulrike
Robertson, John
Suman, Vera
Turnbull, Arran

is schema:about of

named entity 'Evidence-based guidelines'
named entity 'breast cancer'
named entity 'tamoxifen'
named entity '1, 2'
named entity 'Ki67'
named entity 'Group 3'
named entity 'Ki67'
named entity 'Ki67'
named entity 'endocrine'
named entity 'Ki67'
named entity 'details of the trials'
named entity 'tumor'
named entity 'postmenopausal women'
named entity 'letrozole'
named entity 'neoadjuvant chemotherapy'
named entity 'PgR'
named entity 'case-control'
named entity 'neoadjuvant'
named entity 'long-term'
named entity 'Ki67'
named entity 'premenopausal'
named entity 'prognosis'
named entity 'COVID19'
named entity 'tamoxifen'
named entity 'breast cancer'
named entity 'premenopausal'
named entity 'surgical management'
named entity 'chemotherapy'
named entity 'Ki67'
named entity 'Ki67'
named entity 'postmenopausal'
named entity 'adjuvant'
named entity 'Ki67'
named entity 'case-control study'
named entity 'anastrozole'
named entity 'biopsy'
named entity 'clinical trials'
named entity 'PgR'
named entity 'Ki67'
named entity 'meta-analysis'
named entity 'postmenopausal'
named entity 'core biopsy'
named entity 'postmenopausal'
named entity 'Ki67'
named entity 'PgR'
named entity 'biopsy'
named entity 'PgR'
named entity 'postmenopausal'
named entity 'PgR'
named entity 'Ki67'
named entity 'Ki67'
named entity 'Group 3'
named entity 'Ki67'
named entity 'Group 3'
named entity '12 weeks'
named entity 'tumor size'
named entity 'breast cancer'
named entity 'anastrozole'
named entity 'Ki67'
named entity 'postmenopausal'
named entity 'Ki67'
named entity 'biopsy'
named entity 'neoadjuvant'
named entity 'Ki67'
named entity 'ER+'
named entity 'COVID-19 pandemic'
named entity 'postmenopausal'
named entity 'premenopausal'
named entity 'tumor size'
named entity 'postmenopausal'
named entity 'tumors'
named entity 'tumor'
named entity 'PgR'
named entity 'COVID-19'
named entity 'PgR'
named entity 'Ki67'
named entity 'COVID-19'
named entity 'biopsy'
named entity 'ER+'
named entity 'ER+'
named entity 'PgR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software